PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 18, 2026Journal of Pediatric Gastroenterology and Nutrition1 citationsOpen Access

Safety and efficacy of weekly adalimumab 80 mg therapy in pediatric Crohn's disease

View Full Paper
ECEyal Cohen‐SelaAYAnat Yerushalmy‐FelerFRFiras Rinawi

Key Points

  • This research aims to assess the safety and effectiveness of weekly 80 mg adalimumab therapy in children with Crohn's disease.
  • Evaluated pediatric patients experiencing pharmacokinetic loss of response to current treatments.
  • Administered weekly doses of 80 mg adalimumab.
  • Monitored patient outcomes regarding safety and therapeutic efficacy.
  • 80 mg weekly adalimumab demonstrated an effective response in pediatric patients.
  • Treatment was well-tolerated with minimal adverse effects noted.
  • Findings suggest a potential benefit in intensification of therapy.

Abstract

Weekly 80 mg adalimumab appears to be an effective and well-tolerated intensification strategy in pediatric CD patients with pharmacokinetic loss of response. Further prospective studies are needed to confirm these findings and guide optimal use.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Cohen‐Sela et al. (2026) studied this question.

synapsesocial.com/papers/69ba42dc4e9516ffd37a37f8https://doi.org/10.1002/jpn3.70397
Ask AI
Helpful
Bookmark
Share
View Full Paper